Caris Life Sciences (CAI) Financials

$18.95 +0.26 (+1.39%)

Closing price 04:00 PM Eastern

Extended Trading

$18.92 -0.04 (-0.18%)

As of 07:11 PM Eastern

Annual Income Statements for Caris Life Sciences

This table shows Caris Life Sciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2023	2024	2025
Period end date	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-463	-378	-538
Consolidated Net Income / (Loss)	-341	-282	-68
Net Income / (Loss) Continuing Operations	-341	-282	-68
Total Pre-Tax Income	-341	-282	-68
Total Operating Income	-320	-257	45
Total Gross Profit	89	179	539
Total Revenue	306	412	812
Operating Revenue	306	412	812
Total Cost of Revenue	217	233	273
Operating Cost of Revenue	217	233	273
Total Operating Expenses	409	436	494
Selling, General & Admin Expense	149	169	225
Marketing Expense	143	153	168
Research & Development Expense	117	114	102
Total Other Income / (Expense), net	-22	-25	-113
Interest Expense	32	50	57
Interest & Investment Income	11	7.12	16
Other Income / (Expense), net	-1.51	18	-73
Income Tax Expense	0.00	0.00	0.00
Preferred Stock Dividends Declared	121	96	470
Basic Earnings per Share	($13.24)	($10.66)	($3.22)
Weighted Average Basic Shares Outstanding	34.94M	35.50M	167.21M
Diluted Earnings per Share	($13.24)	($10.66)	($3.22)
Weighted Average Diluted Shares Outstanding	34.94M	35.50M	167.21M
Weighted Average Basic & Diluted Shares Outstanding	-	-	282.58M

This table shows Caris Life Sciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q2 2024	Q3 2024	Q2 2025	Q3 2025
Period end date	6/30/2024	9/30/2024	6/30/2025	9/30/2025
Net Income / (Loss) Attributable to Common Shareholders	-90	-92	-517	24
Consolidated Net Income / (Loss)	-66	-68	-72	24
Net Income / (Loss) Continuing Operations	-66	-68	-72	24
Total Pre-Tax Income	-66	-68	-72	24
Total Operating Income	-67	-61	-18	33
Total Gross Profit	38	44	114	148
Total Revenue	100	102	181	217
Operating Revenue	100	102	181	217
Total Cost of Revenue	62	57	68	69
Operating Cost of Revenue	62	57	68	69
Total Operating Expenses	105	105	132	115
Selling, General & Admin Expense	41	41	64	52
Marketing Expense	39	37	42	41
Research & Development Expense	25	28	25	22
Total Other Income / (Expense), net	0.83	-6.89	-54	-8.32
Interest Expense	14	14	19	14
Interest & Investment Income	2.64	1.74	1.62	7.36
Other Income / (Expense), net	12	5.17	-36	-2.17
Income Tax Expense	0.00	0.00	0.00	0.00
Preferred Stock Dividends Declared	24	25	445	0.00
Basic Earnings per Share	($2.54)	($2.59)	($7.97)	$0.09
Weighted Average Basic Shares Outstanding	35.37M	35.64M	64.92M	282.10M
Diluted Earnings per Share	($2.54)	($2.59)	($7.97)	$0.08
Weighted Average Diluted Shares Outstanding	35.37M	35.64M	64.92M	297.21M
Weighted Average Basic & Diluted Shares Outstanding	-	-	281.22M	282.15M

This table details how cash moves in and out of Caris Life Sciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2023	2024	2025
Period end date	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-51	8.02	732
Net Cash From Operating Activities	-276	-245	83
Net Cash From Continuing Operating Activities	-276	-245	83
Net Income / (Loss) Continuing Operations	-341	-282	-68
Consolidated Net Income / (Loss)	-341	-282	-68
Depreciation Expense	49	49	23
Amortization Expense	5.38	7.05	13
Non-Cash Adjustments To Reconcile Net Income	18	9.79	149
Changes in Operating Assets and Liabilities, net	-7.13	-29	-33
Net Cash From Investing Activities	215	53	-16
Net Cash From Continuing Investing Activities	215	53	-16
Purchase of Property, Plant & Equipment	-22	-8.44	-16
Purchase of Investments	-63	0.00	0.00
Sale and/or Maturity of Investments	300	61	0.00
Net Cash From Financing Activities	10	200	665
Net Cash From Continuing Financing Activities	10	200	665
Repayment of Debt	-182	0.00	-4.00
Repurchase of Common Equity	0.00	-1.06	-7.82
Issuance of Debt	191	200	28
Issuance of Preferred Equity	0.00	0.00	121
Issuance of Common Equity	0.00	0.00	539
Other Financing Activities, net	1.12	1.37	-11
Effect of Exchange Rate Changes	0.06	-	0.13
Cash Interest Paid	16	49	44

This table details how cash moves in and out of Caris Life Sciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q4 2024	Q3 2025	Q4 2025
Period end date	9/30/2024	12/31/2024	9/30/2025	12/31/2025
Net Change in Cash & Equivalents	-71	-41	34	43
Net Cash From Operating Activities	-69	-39	62	45
Net Cash From Continuing Operating Activities	-69	-41	62	45
Net Income / (Loss) Continuing Operations	-68	-37	24	82
Consolidated Net Income / (Loss)	-68	-37	24	82
Depreciation Expense	11	9.07	4.87	4.29
Amortization Expense	1.83	1.91	2.46	0.61
Non-Cash Adjustments To Reconcile Net Income	3.65	-7.82	17	17
Changes in Operating Assets and Liabilities, net	-17	-6.97	14	-59
Net Cash From Investing Activities	-1.83	-2.29	-7.10	-5.09
Net Cash From Continuing Investing Activities	-1.83	-2.29	-7.10	-5.09
Purchase of Property, Plant & Equipment	-1.83	-2.29	-7.10	-5.09
Net Cash From Financing Activities	0.09	0.23	-21	3.40
Net Cash From Continuing Financing Activities	0.09	0.23	-21	3.40
Repurchase of Common Equity	-0.54	-0.03	-5.67	-0.09
Other Financing Activities, net	0.63	0.25	-15	3.49

This table presents Caris Life Sciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2025
Period end date	12/31/2024	12/31/2025
Total Assets	344	1,126
Total Current Assets	216	998
Cash & Equivalents	65	798
Short-Term Investments	2.20	2.30
Accounts Receivable	88	112
Inventories, net	40	64
Prepaid Expenses	20	22
Plant, Property, & Equipment, net	68	63
Total Noncurrent Assets	60	65
Goodwill	19	19
Other Noncurrent Operating Assets	41	45
Total Liabilities & Shareholders' Equity	344	1,126
Total Liabilities	621	548
Total Current Liabilities	165	127
Short-Term Debt	60	0.17
Accounts Payable	28	39
Accrued Expenses	78	88
Total Noncurrent Liabilities	455	421
Long-Term Debt	319	379
Other Noncurrent Operating Liabilities	136	42
Commitments & Contingencies	0.00	0.00
Redeemable Noncontrolling Interest	2,222	0.00
Total Equity & Noncontrolling Interests	-2,499	577
Total Preferred & Common Equity	-2,499	577
Preferred Stock	0.00	0.00
Total Common Equity	-2,499	577
Common Stock	0.04	3,142
Retained Earnings	-2,472	-2,549
Treasury Stock	-0.33	-17
Accumulated Other Comprehensive Income / (Loss)	0.21	0.94
Other Equity Adjustments	-26	0.00

This table presents Caris Life Sciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2025	Q3 2025
Period end date	6/30/2025	9/30/2025
Total Assets	955	985
Total Current Assets	833	854
Cash & Equivalents	-	755
Short-Term Investments	2.25	2.27
Accounts Receivable	51	27
Inventories, net	41	49
Prepaid Expenses	19	21
Plant, Property, & Equipment, net	61	64
Total Noncurrent Assets	60	66
Goodwill	19	19
Other Noncurrent Operating Assets	41	47
Total Liabilities & Shareholders' Equity	955	985
Total Liabilities	502	506
Total Current Liabilities	90	86
Short-Term Debt	0.10	0.16
Accounts Payable	29	29
Accrued Expenses	61	57
Total Noncurrent Liabilities	412	420
Long-Term Debt	374	376
Other Noncurrent Operating Liabilities	38	44
Commitments & Contingencies	0.00	0.00
Redeemable Noncontrolling Interest	0.00	0.00
Total Equity & Noncontrolling Interests	453	478
Total Preferred & Common Equity	453	478
Preferred Stock	0.00	0.00
Total Common Equity	453	478
Common Stock	3,124	3,125
Retained Earnings	-2,655	-2,631
Treasury Stock	-17	-17
Accumulated Other Comprehensive Income / (Loss)	0.67	0.75
Other Equity Adjustments	-	0.00

This table displays calculated financial ratios and metrics derived from Caris Life Sciences' official financial filings.

Metric	2023	2024	2025
Period end date	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	0.00	0.00	282,146,923.00
DEI Adjusted Shares Outstanding	0.00	0.00	282,146,923.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	0.00	-1.91
Growth Metrics	-	-	-
Profitability Metrics	-	-	-
Net Operating Profit after Tax (NOPAT)	-224	-180	32
Return On Investment Capital (ROIC_SIMPLE)	-	8.49%	3.30%
Earnings before Interest and Taxes (EBIT)	-321	-239	-28
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-267	-183	7.65
Valuation Ratios	-	-	-
Leverage & Solvency	-	-	-
Liquidity Ratios	-	-	-
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-215	-90
Efficiency Ratios	-	-	-
Capital & Investment Metrics	-	-	-
Invested Capital	0.00	35	156
Increase / (Decrease) in Invested Capital	0.00	35	122
Book Value per Share	$0.00	($70.40)	$2.05
Tangible Book Value per Share	$0.00	($70.94)	$1.98
Total Capital	0.00	102	956
Total Debt	0.00	380	379
Total Long-Term Debt	0.00	319	379
Net Debt	0.00	312	-421
Capital Expenditures (CapEx)	22	8.44	16
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	43	71
Debt-free Net Working Capital (DFNWC)	0.00	110	871
Net Working Capital (NWC)	0.00	50	871
Net Nonoperating Expense (NNE)	118	102	100
Net Nonoperating Obligations (NNO)	0.00	312	-421
Total Depreciation and Amortization (D&A)	54	56	35
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($3.22)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	167.21M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($3.22)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	167.21M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	282.58M
Normalized Net Operating Profit after Tax (NOPAT)	-224	-180	32
Debt Service Ratios	-	-	-
Payout Ratios	-	-	-

This table displays calculated financial ratios and metrics derived from Caris Life Sciences' official financial filings.

Metric	Q2 2024	Q3 2024	Q2 2025	Q3 2025
Period end date	6/30/2024	9/30/2024	6/30/2025	9/30/2025
DEI Shares Outstanding	0.00	0.00	0.00	281,224,124.00
DEI Adjusted Shares Outstanding	0.00	0.00	0.00	281,224,124.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	0.00	0.00	0.09
Growth Metrics	-	-	-	-
Revenue Growth	0.00%	0.00%	81.31%	113.38%
EBITDA Growth	0.00%	0.00%	1.73%	187.28%
EBIT Growth	0.00%	0.00%	1.73%	154.73%
NOPAT Growth	0.00%	0.00%	73.16%	176.64%
Net Income Growth	0.00%	0.00%	-8.47%	135.92%
EPS Growth	0.00%	0.00%	-213.78%	103.09%
Operating Cash Flow Growth	0.00%	0.00%	0.00%	189.91%
Free Cash Flow Firm Growth	0.00%	0.00%	0.00%	0.00%
Invested Capital Growth	0.00%	0.00%	0.00%	0.00%
Revenue Q/Q Growth	0.00%	1.57%	0.00%	19.53%
EBITDA Q/Q Growth	0.00%	21.46%	0.00%	169.75%
EBIT Q/Q Growth	0.00%	-0.95%	0.00%	156.22%
NOPAT Q/Q Growth	0.00%	9.21%	0.00%	359.22%
Net Income Q/Q Growth	0.00%	-2.33%	0.00%	133.88%
EPS Q/Q Growth	0.00%	-1.97%	0.00%	101.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	44.06%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	-5.87%
Profitability Metrics	-	-	-	-
Gross Margin	37.54%	43.70%	62.67%	68.03%
EBITDA Margin	-55.13%	-42.63%	-29.88%	17.44%
Operating Margin	-66.98%	-59.87%	-9.92%	15.05%
EBIT Margin	-55.13%	-54.79%	-29.88%	14.05%
Profit (Net Income) Margin	-66.15%	-66.65%	-39.58%	11.22%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	120.01%	121.65%	132.45%	79.83%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	0.00%	0.00%	0.00%	0.00%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	0.00%	0.00%	0.00%	0.00%
Return on Equity Simple (ROE_SIMPLE)	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-47	-43	-13	33
NOPAT Margin	-46.88%	-41.91%	-6.94%	15.05%
Net Nonoperating Expense Percent (NNEP)	0.00%	0.00%	-33.93%	-4.37%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-1.52%	3.82%
Cost of Revenue to Revenue	62.46%	56.30%	37.33%	31.97%
SG&A Expenses to Revenue	41.05%	40.20%	35.48%	23.97%
R&D to Revenue	24.77%	27.20%	13.81%	9.97%
Operating Expenses to Revenue	104.51%	103.58%	72.59%	52.97%
Earnings before Interest and Taxes (EBIT)	-55	-56	-54	30
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-55	-43	-54	38
Valuation Ratios	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	3.83	18.79
Price to Tangible Book Value (P/TBV)	0.00	0.00	4.00	19.59
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	13.33	88.03
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-
Debt to Equity	0.00	0.00	0.83	0.79
Long-Term Debt to Equity	0.00	0.00	0.82	0.79
Financial Leverage	0.00	0.00	-0.77	-0.80
Leverage Ratio	0.00	0.00	2.11	2.06
Compound Leverage Factor	0.00	0.00	2.79	1.64
Debt to Total Capital	0.00%	0.00%	45.21%	44.04%
Short-Term Debt to Total Capital	0.00%	0.00%	0.01%	0.02%
Long-Term Debt to Total Capital	0.00%	0.00%	45.20%	44.02%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	0.00%	54.79%	55.96%
Debt to EBITDA	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	0.00	0.00	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-
Current Ratio	0.00	0.00	9.24	9.93
Quick Ratio	0.00	0.00	0.59	9.11
Cash Flow Metrics	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	0.00	-117	-65
Operating Cash Flow to CapEx	0.00%	-3,797.98%	0.00%	879.85%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-6.07	-4.83
Operating Cash Flow to Interest Expense	0.00	-5.03	0.00	4.62
Operating Cash Flow Less CapEx to Interest Expense	0.00	-5.16	0.00	4.10
Efficiency Ratios	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-
Invested Capital	0.00	0.00	104	98
Invested Capital Turnover	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	0.00	0.00	104	98
Enterprise Value (EV)	0.00	0.00	1,386	8,610
Market Capitalization	494	494	1,735	8,991
Book Value per Share	$0.00	$0.00	$6.98	$1.70
Tangible Book Value per Share	$0.00	$0.00	$6.68	$1.63
Total Capital	0.00	0.00	827	855
Total Debt	0.00	0.00	374	376
Total Long-Term Debt	0.00	0.00	374	376
Net Debt	0.00	0.00	-349	-381
Capital Expenditures (CapEx)	0.00	1.83	0.00	7.10
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	0.00	21	11
Debt-free Net Working Capital (DFNWC)	0.00	0.00	743	768
Net Working Capital (NWC)	0.00	0.00	743	768
Net Nonoperating Expense (NNE)	19	25	59	8.32
Net Nonoperating Obligations (NNO)	0.00	0.00	-349	-381
Total Depreciation and Amortization (D&A)	0.00	12	0.00	7.33
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($7.97)	$0.09
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	64.92M	282.10M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($7.97)	$0.08
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	64.92M	297.21M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	281.22M	282.15M
Normalized Net Operating Profit after Tax (NOPAT)	-47	-43	-13	23
Normalized NOPAT Margin	-46.88%	-41.91%	-6.94%	10.54%
Pre Tax Income Margin	-66.15%	-66.65%	-39.58%	11.22%
Debt Service Ratios	-	-	-	-
EBIT to Interest Expense	-4.03	-4.03	-2.82	2.26
NOPAT to Interest Expense	-3.43	-3.09	-0.66	2.42
EBIT Less CapEx to Interest Expense	0.00	-4.17	0.00	1.73
NOPAT Less CapEx to Interest Expense	0.00	-3.22	0.00	1.89
Payout Ratios	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Below are key takeaways from Caris Life Sciences (CAI) quarterly statements covering the last four quarters available (2024 Q3–2025 Q4). The bullets focus on indicators that may influence investors, with positive items listed first, then neutral, then negative.

Revenue growth in 2025: 2025 Q3 total revenue reached $216,833,000, up from $101,620,000 in 2024 Q3 (roughly a 113% year-over-year increase), signaling a meaningful expansion in top-line activity.
Operating cash flow turns positive in 2025: Net cash from continuing operating activities was $62,425,000 in 2025 Q3, indicating improved cash generation from core operations.
Continued positive cash flow into Q4 2025: Net cash from continuing operating activities remained positive at $44,780,000 in 2025 Q4, reinforcing the cash-generation trend.
Balance sheet growth in 2025 Q3: Total assets increased to $984,571,000 (from $955,058,000 in 2025 Q2), reflecting a larger asset base.
Equity base expands in 2025 Q3: Total equity climbed to $478,364,000 in 2025 Q3, up from $452,904,000 in 2025 Q2, contributing to a stronger balance sheet position.
Deficit narrowing in 2025 Q3: Retained earnings improved modestly, narrowing the accumulated deficit from $(2,655,018,000) in 2025 Q2 to $(2,630,693,000) in 2025 Q3.
Financing activity adds small cash inflow in 2025 Q3: Net cash from continuing financing activities was $3,399,000 in 2025 Q3, providing a modest liquidity boost from financing activities.
Investing cash outflows are modest and stabilizing: Cash used for purchases of property, plant, and equipment remained small (e.g., $7,095,000 in 2025 Q3 and $5,090,000 in 2025 Q4), with consistent but manageable investing outflows.
Debt levels show small increases: Short-term debt rose to $164,000 and long-term debt to $376,296,000 in 2025 Q3 (up modestly from 2025 Q2), indicating incremental leverage without large jumps.
Historical net losses through mid-2025: Net income attributable to common shareholders remained negative through 2025 Q2 and Q3 (approximately -$517.2 million in those quarters), though results swing positive by 2025 Q4, highlighting a volatile profitability trajectory.

05/05/26 10:13 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Caris Life Sciences' Financials

When does Caris Life Sciences' fiscal year end?

According to the most recent income statement we have on file, Caris Life Sciences' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

How has Caris Life Sciences' net income changed over the last 2 years?

Caris Life Sciences' net income appears to be on a downward trend, with a most recent value of -$68.09 million in 2025, falling from -$341.42 million in 2023. The previous period was -$281.89 million in 2024. View Caris Life Sciences' forecast to see where analysts expect Caris Life Sciences to go next.

What is Caris Life Sciences' operating income?

Caris Life Sciences' total operating income in 2025 was $45.11 million, based on the following breakdown:

Total Gross Profit: $539.17 million
Total Operating Expenses: $494.06 million

How has Caris Life Sciences' revenue changed over the last 2 years?

Over the last 2 years, Caris Life Sciences' total revenue changed from $306.13 million in 2023 to $812.03 million in 2025, a change of 165.3%.

How much debt does Caris Life Sciences have?

Caris Life Sciences' total liabilities were at $548.36 million at the end of 2025, a 11.7% decrease from 2024, and a 11.7% decrease since 2024.

How much cash does Caris Life Sciences have?

In the past 1 years, Caris Life Sciences' cash and equivalents has ranged from $65.44 million in 2024 to $797.80 million in 2025, and is currently $797.80 million as of their latest financial filing in 2025.

How has Caris Life Sciences' book value per share changed over the last 2 years?

Over the last 2 years, Caris Life Sciences' book value per share changed from 0.00 in 2023 to 2.05 in 2025, a change of 204.6%.

Related Companies

Financial statements for NASDAQ:CAI last updated on 4/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Caris Life Sciences (CAI) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Caris Life Sciences' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Caris Life Sciences (CAI) Financials

Annual Income Statements for Caris Life Sciences

Quarterly Income Statements for Caris Life Sciences

Annual Cash Flow Statements for Caris Life Sciences

Quarterly Cash Flow Statements for Caris Life Sciences

Annual Balance Sheets for Caris Life Sciences

Quarterly Balance Sheets for Caris Life Sciences

Annual Metrics And Ratios for Caris Life Sciences

Quarterly Metrics And Ratios for Caris Life Sciences

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Caris Life Sciences' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools